Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells $9,393,750.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $417.50, for a total transaction of $9,393,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $427.41, for a total transaction of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $440.35, for a total transaction of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $450.24, for a total transaction of $10,130,400.00.
• On Monday, September 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $421.80, for a total transaction of $9,490,500.00.
• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $416.35, for a total value of $9,367,875.00.
• On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $400.56, for a total value of $9,012,600.00.
• On Monday, September 8th, Michael Benkowitz sold 5,000 shares of United Therapeutics stock. The stock was sold at an average price of $392.21, for a total value of $1,961,050.00.
• On Tuesday, September 9th, Michael Benkowitz sold 11,375 shares of United Therapeutics stock. The stock was sold at an average price of $397.41, for a total value of $4,520,538.75.
• On Tuesday, September 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $453.53 on Friday. The business has a 50 day simple moving average of $407.40 and a 200 day simple moving average of $336.86. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $479.50. The stock has a market cap of $20.46 billion, a price-to-earnings ratio of 17.19, a PEG ratio of 4.96 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.39 earnings per share. On average, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of UTHR. CWM LLC grew its position in shares of United Therapeutics by 204.3% in the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after acquiring an additional 3,487 shares during the period. XTX Topco Ltd bought a new position in shares of United Therapeutics in the 1st quarter valued at about $313,000. Allianz Asset Management GmbH lifted its stake in United Therapeutics by 96.9% in the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock valued at $20,832,000 after purchasing an additional 33,254 shares during the last quarter. LPL Financial LLC lifted its stake in United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after purchasing an additional 11,007 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock valued at $1,129,000 after purchasing an additional 376 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on UTHR. UBS Group boosted their price objective on shares of United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research report on Monday, September 29th. Royal Bank Of Canada lifted their price target on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday. Oppenheimer increased their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of United Therapeutics in a research report on Wednesday, October 8th. Finally, Bank of America upped their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Seven investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $483.73.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.